Recent news highlights Syra Health's contract awards and financial performance updates, reflecting ongoing business activity and operational progress.

• Syra Health won a $5.8 million contract in Indiana to lead a child mental health access site [N13].
• The company was awarded a $1 million contract for healthcare services in Washington D.C. [N14].
• Syra Health received a healthcare workforce contract and contract extension [N15].
• The company reported Q3 earnings per share of $0.06 compared to a loss of $0.21 in the prior year [N12].
• Syra Health priced a $2.1 million public offering of shares and warrants in September 2024 [N16].
• Syra Health serves as a subcontractor for Luke for the Defense Health Agency [N17].

Syra Health has demonstrated the ability to secure significant government contracts, including a $5.8 million contract in Indiana and a $1 million contract in Washington D.C., which support revenue generation. The company reported positive net income and earnings per share in the latest quarter, indicating operational progress. Strong liquidity ratios provide financial flexibility. Experienced leadership with a track record in healthcare growth initiatives supports strategic execution.

Syra Health operates in a competitive healthcare services market with reliance on government contracts, which may be subject to renewal risks and regulatory changes. The company has a relatively small market capitalization and limited public financial history, which may constrain access to capital. Execution risks include scaling operations and maintaining profitability amid evolving healthcare policies and reimbursement environments.

Syra Health's moat is derived from its specialized focus on healthcare workforce services and mental health access, supported by government contracts and partnerships. Its leadership's deep expertise in healthcare markets and technology, along with established relationships with public sector clients, contribute to competitive positioning. However, the company operates in a competitive and regulated environment where contract renewals and regulatory changes can impact its business.

• Contract Dependency Risk: The company relies heavily on government contracts for revenue, which may be subject to non-renewal or changes in government spending priorities.
• Regulatory Risk: Changes in healthcare regulations and policies could adversely affect the company's operations and financial performance.
• Execution Risk: Scaling operations and managing growth while maintaining profitability pose challenges, especially in a competitive healthcare services market.

• Syra Health Corp is a healthcare company registered in Delaware, trading under ticker SYRA on OTC QB market [S1].
• As of March 12, 2026, Syra Health had 11,339,169 shares of Class A Common Stock outstanding [S1].
• The company operates in the healthcare sector with a focus on healthcare workforce and mental health access services [N13, N14, N15].
• Syra Health has been awarded multiple government contracts including a $5.8 million contract in Indiana to lead a child mental health access site, a $1 million contract for healthcare services in Washington D.C., and a healthcare workforce contract and extension [N13, N14, N15].
• The company reported financial results for the quarter ended June 30, 2026, with revenue of $2,394,423 and net income of $250,242 [S2].
• Basic and diluted earnings per share for Q2 2026 were $0.02 [S2].
• As of June 30, 2026, Syra Health had cash and cash equivalents of $2,123,747 and current assets of $3,747,154, with current liabilities of $1,196,152, resulting in a current ratio of 3.13 and a cash ratio of 1.78, indicating strong liquidity [S2].
• The company completed a $2.1 million public offering of shares and warrants in September 2024 [N16].
• Leadership includes CEO Gregory R. Alexander since January 2026, with extensive experience in healthcare technology and population health, and CFO/COO Priya Prasad since January 2023 [S1].
• The board of directors includes members with backgrounds in pharmaceutical research, healthcare technology, and business operations [S1].
• Syra Health serves as a subcontractor for the Defense Health Agency [N17].
• The company reported Q3 EPS of $0.06 compared to a loss of $0.21 the prior year [N12].